摘要
Dear Editor,Diffuse large B-cell lymphoma(DLBCL)is the most common and aggressive subtype of non-Hodgkin lymphoma(NHL),accounting for about 40%of all NHL cases[1].Lacking symptoms at early time and efficient therapeutic methods made DLBCL one of the most life-threatening types of hematopoietic malignancy[2,3].Therefore,identifying novel therapeutic biomarker for early detection and prognosis prediction is urgently needed.
基金
This work was supported by the National Natural Science Foundation of China(81802424).
